AstraZeneca plc (LSE:AZN; NYSE:AZN) said at an investor day on Thursday that it is aiming to double its Phase III pipeline by 2016 and will focus small and large molecule R&D on three core areas: respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and cancer. Pascal Soriot, who took over as CEO in October, said the pharma is aiming to create a portfolio with specialty care products to balance AstraZeneca's expertise in primary care.
Well, the strategy is very clear... But why just double? Go further!
No comments:
Post a Comment